Features of treatment of C. difficile associated diarrhea in patients with new coronavirus infection
https://doi.org/10.33667/2078-5631-2022-28-12-14
Abstract
The pandemic of a new coronavirus infection in recent years has led to more frequent and aggressive prescription of antibiotic therapy, which could not but affect the intestinal microbiota. In addition, the direct effect of coronavirus on enterocytes leads to the development of subclinical inflammation in the intestinal wall, contributing to the disruption of the qualitative and quantitative composition of the normal intestinal microflora. Against this background, the number of patients with antibiotic-associated diarrhea, including diarrhea caused by C. difficile, including severe ones. Moreover, the number of clostridial diarrhea resistant to classical vancomycin therapy has increased, which dictates the need to find new ways to treat patients and methods for further prevention of such conditions.
About the Authors
M. S. Turchina
Orel State University n.a. I.S. Turgenev
Russian Federation
Russian Federation
PhD Med, associate professor at Dept of Internal Diseases
Orel
M. V. Bukreeva
Orel State University n.a. I.S. Turgenev
Russian Federation
Russian Federation
seniour lecturer at Dept of Internal Medicine
Orel
L. Yu. Koroleva
Orel State University n.a. I.S. Turgenev
Russian Federation
Russian Federation
seniour lecturer at Dept of Internal Medicine
Orel
Yu. M. Morozov
Orel State University n.a. I.S. Turgenev
Russian Federation
Russian Federation
head of Dept of Specialized Surgical Disciplines
Orel
T. I. Obolenskaya
Orel State University n.a. I.S. Turgenev
Russian Federation
Russian Federation
associate professor at Dept of Immunology and Specialized Clinical Disciplines
Orel
References
1. Granata G., Bartoloni A., Codeluppi M., Contadini I. et al. The Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals (CloVid). J Clin Med. 2020. No. 9. E3855. DOI: 10.3390/jcm9123855.
2. Garrigues E., Janvier P., Kherabi Y., Le Bot A. et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020. No. 81 (6). P. 4–6. DOI: 10.1016/j.jinf.2020.08.029.
3. Тимофеева А.А., Шульпекова Ю.О., Нечаев В.М., Схиртладзе М. Р. Инфекция Сlostridium difficile у пациентки с COVID-19. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021. № 31 (3). С. 68–73. DOI: 10.22416/1382–4376–2021–31–3–68–73. Timofeeva A. A., Shulpekova Yu.O., Nechaev V. M., Shirtladze M.R. Clostridium difficile infection in a patient with COVID-19. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021. No. 31 (3). P. 68–73. DOI: 10.22416/1382–4376–2021–31–3–68–73.
4. Ивашкин В.Т., Ющук Н.Д., Маев И.В., Лапина Т.Л. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению Clostridium difficileассоциированной болезни. Российский журнал гастроэнтерологии гепатологии, колопроктологии. 2016. № 26 (5). С. 56–65. Ivashkin V. T., Yuschuk N. D., Maev I. V., Lapina T. L. i dr. Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of Clostridium difficile-associated disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016. No. 26 (5). P. 56–65.
5. Шелыгин Ю. А., Алёшкин В. А., Сухина М. А. и др. Клинические рекомендации Национальной ассоциации специалистов по контролю инфекций, связанных с оказанием медицинской помощи, и Общероссийской общественной некоммерческой организации «Ассоциация колопроктологов России» по диагностике, лечению и профилактике Clostridium difficile-ассоциированной диареи (CDI). Колопроктология. 2018. № 3 (65). С. 7–23. DOI: 10.33878/2073–7556–2018–0–3–7–23. Sheligin Yu.A., Aleshkin V. A., Suhina M. A. et al. Clinical guidelines of the National Association of Infection Control Specialists associated with the provision of medical care and the All-Russian public non-profit organization ‘Association of Coloproctologists of Russia on the diagnosis, treatment and prevention of Clostridium difficile-associated diarrhea (CDI)’. Coloproctology. 2018. No. 3 (65). P. 7–23. DOI: 10.33878/2073–7556–2018–0–3–7–23.
6. Осипенко М.Ф., Бикбулатова Е. А., Холин С.И. Профилактика и лечение антибиотико-ассоциированной диареи: место пробиотиков. Медицинский совет. 2017. № 11. С. 104–106. DOI: 10.21518/2079–701X-2017–104–106. Osipenko M.F., Bikbulatova E.A., Holin S.I. Prevention and treatment of antibiotic-associated diarrhea: the place of probiotics. Medical Advice. 2017. No. 11. P. 104–106. DOI: 10.21518/2079–701X-2017–104–106.
7. Сухина М. А., Макешова А. Б., Шелыгин Ю. А., Кашников В.Н. Механизмы антибактериальной резистентности Clostridium (clostridioides) difficile. Экспериментальная и клиническая гастроэнтерология. 2018. № 160 (12). С. 70–79. DOI: 10.31146/1682–8658-ecg-160–12–70–79. Suhina M. A., Makeshova A. B., Sheligin Yu.A., Kashnikov V. N. Mechanisms of antibacterial resistance of Clostridium (clostridioides) difficile. Experimental and Clinical Gastroenterology. 2018. No. 160 (12). P. 70–79. DOI: 10.31146/1682–8658-ecg-160–12–70–79.
8. Зырянов С. К., Байбулатова Е. А. Рифаксимин-альфа и другие кристаллические формы рифаксимина: есть ли отличия? Антибиотики и химиотерапия. 2020. № 65 (7–8). С. 52–62. DOI: 10.37489/0235–2990–2020–65–7–8–52–62. Ziryanov S.K., Baibulatova E.A. Rifaximin-alpha and other crystalline forms of rifaximin: Are there any differences? Antibiotics and Chemotherapy. 2020. No. 65 (7–8). P. 52–62. DOI: 10.37489/0235–2990–2020–65–7–8–52–62.
Review
For citations:
Turchina M.S., Bukreeva M.V., Koroleva L.Yu., Morozov Yu.M., Obolenskaya T.I. Features of treatment of C. difficile associated diarrhea in patients with new coronavirus infection. Medical alphabet. 2022;1(28):12-14. (In Russ.) https://doi.org/10.33667/2078-5631-2022-28-12-14
Views:
306
Email this article 